Introduction
Amyloid-β (Aβ) peptide accumulation in the central nervous system underlies the pathological process in Alzheimer's disease (AD) and these peptides are formed from proteolytic cleavage of the amyloid precursor protein (APP), an integral membrane protein. β-secretase (BACE) and γ-secretase are the proteases responsible for cleaving the Aβ peptide from APP on the amino-and carboxy-termini, respectively. The Seladin-1 gene (Selective Alzheimer's Disease Indicator-1) was originally identified based on its selective downregulation of expression in regions of the brain vulnerable to AD relative to normal brains (Greeve et al., 2000; Iivonen et al., 2002) . In cell culture, increased Seladin-1 expression was protective against Aβ toxicity and oxidative stress induced apoptosis (Greeve et al., 2000) .
A link between cholesterol metabolism and AD has been recognized for some time (Puglielli et al., 2003) . High plasma low density lipoprotein (LDL) levels as well as the ε4 genotype of the major brain lipoprotein, apolipoprotein E, are associated with increased risk of development of AD (Fernandes et al., 1999; Kuo et al., 1998) . Relative to age matched controls, AD patients have higher serum levels of LDL and reduced plasma levels of high density lipoprotein (Fernandes et al., 1999; Kuo et al., 1998) Additionally, LDL lowering agents such as the statins have been shown to be associated with decreased risk of developing AD (Jick et al., 2000) .
Seladin-1/DHCR24 encodes the 3β-hydroxysterol-∆24 reductase enzyme responsible for catalyzing the reduction of the ∆24 bond of sterol intermediates within the cholesterologenic pathway and is widely expressed (Waterham et al., 2001) . DHCR24 is responsible for reducing the ∆24 double bond of desmosterol to produce cholesterol and This article has not been copyedited and formatted. The final version may differ from this version.
Molecular Pharmacology Fast Forward. Published on September 24, 2008 as DOI: 10.1124 at ASPET Journals on June 20, 2017 molpharm.aspetjournals.org Downloaded from deficiency in the DHCR24 gene leads to desmosterolosis in humans, which is associated with elevated levels of plasma desmosterol and developmental abnormalities (Waterham et al., 2001) . Seladin1/DHCR24 has also been shown to be important in the formation of cholesterol-enriched lipid rafts or detergent-resistant membrane domains (DRMs) (Crameri et al., 2006) . Since DRMs play an essential role in organization of integral membrane proteins required for cellular signaling pathways, the importance of Seladin1/DHCR24 is clear (Simons and Toomre, 2000) .
DRMs have been found to be disorganized in AD brains and this is associated with abnormal proteolytic cleavage of APP (Ledesma et al., 2003) . APP processing has been shown to be associated with lipid rafts (Ehehalt et al., 2003) and the rafts contribute to partitioning APP from BACE thus limiting APP β-cleavage and subsequent production of Aβ (Abad-Rodriguez et al., 2004) . Decreased levels of Seladin-1 appear to disturb normal lipid raft formation due to low membrane cholesterol levels leading to altered APP-BACE compartmentalization (Crameri et al., 2006) . This leads to increased APP β-cleavage and Aβ production both in cell culture and in Seladin-1 deficient mice (Crameri et al., 2006) . A specific inhibitor of Seladin-1/DHCR24 has been shown to increase Aβ accumulation (Cecchi et al., 2008) .
The liver X receptors (LXRα [NR1H3] and LXRβ [NR1H2]) are nuclear hormone receptors that function as receptors for oxidized cholesterol metabolites and regulate several pathways involved in lipid and cholesterol metabolism Zelcer and Tontonoz, 2006) . LXRs have been shown to regulate cholesterol metabolism in the brain and both LXRα and LXRβ are expressed in the brain, although
LXRβ is expressed at considerably higher levels (Whitney et al., 2002) .
LXR ligands
This article has not been copyedited and formatted. The final version may differ from this version. have been shown to modulate APP/Aβ processing in vitro (Brown et al., 2004; Koldamova et al., 2003; Sun et al., 2003) and decrease Aβ accumulation and AD pathology in mouse models of AD (Koldamova et al., 2005; Riddell et al., 2007; Zelcer et al., 2007) . Based on these studies, many have suggested that LXR agonists may be useful to treat or prevent AD.
Here, we describe the identification and characterization of the Seladin-1/DHCR24 gene as an LXR target gene. Our data suggest that LXR may play a role in Seladin-1/DHCR24 mediated regulation of lipid raft formation.
This article has not been copyedited and formatted. The final version may differ from this version. Cell culture and transfections -HepG2 cells were maintained and routinely propagated in MEM supplemented with 10% fetal bovine serum at 37°C under 5% CO 2 as previously described Stayrook et al., 2005) .HEK293 cells were maintained in DMEM supplemented with 10% fetal bovine serum at 37°C under 5% CO 2. Twenty four hours prior to transfection, HepG2 or HEK293 cells were plated in 96-well plates at a density of 15 × 10 3 cells/well. Each transfection contained 100 ng of the pTAL-Luc reporter, 50 ng pGL4.73 reporter and 100 ng receptor as described in the figure legend using Lipofectamine TM 2000 (Invitrogen, CA). Sixteen h post-transfection, cells were treated with LXR ligands. Twenty-four h post-treatment, the luciferase activity was measured using Dual-Glo™ Luciferase Assay System (Promega, WI). Three LXR agonist were utilized in the cotransfection: GW3965 (1µM), T0901317 (1µM), or 22R-hydroxycholesterol (10µM). All these compounds were obtained from Sigma (St. Louis,
MO).
Electrophoretic mobility shift assays (EMSAs)-LXRα and RXRα were expressed using coupled in vitro transcription and translation. EMSAs were performed using the [α-
33 P]dCTP labeled DHCR24 LXRE oligonucleotide. Competition assays were performed using various amounts of the unlabeled DHCR24 LXRE or ABCA1 LXRE oligonucleotide as previously described (Burris et al., 1995) .
This article has not been copyedited and formatted. The final version may differ from this version. ChIP-chip Analysis-ChIP/microarrays were performed from HuH7 as previously described (Stayrook et al., 2008) . Putative LXREs within the region of the Seladin-1/DHCR24 gene identified as LXR bound were identified using NHR scan (Sandelin and Wasserman, 2005) .
Analysis of Seladin-1/Dhcr24 expression in LXRβ WT and KO mice -Skin and whole
brains from newborn (2-3 days old) LXRβ WT and KO mice (Deltagen, San Carlos, CA) was harvested. RNAs were isolated and purified using RNeasy column (Qiagen, Hilden, Germany). cDNA was made and subjected to Taqman assays as per vendor's protocol using ABI 7900HT real-time PCR machine. Dhcr24 taqman assay (Applied Biosystems) was performed to detect the expression level of Dhcr24 in the skin samples from LXRβ WT and KO mice. The relative gene expression level was determined using ∆∆Ct
method.
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Results
We used ChIP-on-chip technology to identify LXRα occupancy sites within the genome.
As previously described, we overexpressed Flag-tagged LXRα in hepatoma (HuH7) cells and identified regions within the genome with significant LXR occupancy (Stayrook et al., 2008) . LXRα occupancy regions were screened for putative LXREs using previously described algorithims (Sandelin and Wasserman, 2005; Varga and Su, 2007 ). LXRα occupancy regions were then queried against the human genome database and 1304
unique genes were identified with a LXRα occupancy region within 1 kb of a gene. This data was then compared with microarray data obtained from the livers of mice treated with a LXR-directed antisense oligonucleotide that significantly reduced LXR expression (Hu et al., 2005) . Thus, we identified genes that were significantly altered by LXR depletion that also demonstrated LXRα occupancy and contained a defined LXRE.
Fifty-seven genes were identified and included the known LXR target genes such as ABCA1 and NR1H3. The Seladin-1/DHCR24 gene was identified in this fashion and based on the relationship of this gene to cholesterol biosynthesis, lipid raft formation, and AD pathology; we decided to examine the LXR regulation of this gene further.
The LXR occupancy site detected by ChIP-on-chip is a ~1.5kb region within the 2 nd intron of the Seladin-1/DHCR24 gene (Fig. 1a) . As indicated above, we noted a decrease in Seladin-1/DHCR24 gene expression in mice treated with a LXR antisense oligonucleotide. We also examined the expression of this gene in LXR null mice.
Cholesterol is a component of the lipid barrier of the skin and skin cells have a very active cholesterol biosynthetic pathway (Feingold, 2007) . The LXRs are expressed in skin with LXRβ being the predominant subtype (Schmuth et al., 2008) . Thus, we used This article has not been copyedited and formatted. The final version may differ from this version. We identified a putative LXRE within the LXR occupancy site identified by ChIP-on-chip using NHR scan (Sandelin and Wasserman, 2005) . A single putative LXRE with a DR4 configuration was identified and is compared to other DR4 LXREs from the well-characterized LXREs from the ABCA1 and NR1H3 genes in Fig. 2a . Fig.   2b shows the results of an electrophoretic mobility shift assay where the binding of the LXRα/RXRα heterodimer to the DHCR24 LXRE is demonstrated. Neither LXRα nor
RXRα alone bound to the element indicating that only the heterodimer binds to the element as expected. Binding of the heterodimer to the radiolabeled DHCR24 element was dose-dependently reduced by addition of unlabeled DHCR24 or ABCA1 LXRE oligonucleotides (1X, 10X or 100X molar excess) (Fig. 2b) .
This article has not been copyedited and formatted. The final version may differ from this version. In order to examine the ability of the DHCR24 LXRE to mediate transcriptional activation by LXR, we cloned 3 copies of this LXRE upstream of a luciferase reporter and transfected this reporter into HepG2 cells that were treated with LXR agonists (T1317, GW3965, or 22R OHC). As shown in Fig. 3a , the LXR ligands did not alter transcription of a control reporter lacking LXREs within the promoter. As a positive control, a luciferase reporter containing 3 copies of the LXRE derived from the LXR target gene NR1H3 in the promoter was transfected into HepG2 cells and treated with the LXR ligands. All three LXR ligands induced transcription with the two synthetic LXR ligands, T1317 and GW3965, displaying greater efficacy than the natural oxysterol ligand, 22R OHC (Fig. 3b) . The reporter gene containing the DHCR24 LXRE showed similar results with the LXR agonists inducing transcription with an identical rank order of efficacy as the NR1H3 reporter construct (Fig. 3b) . These data indicate that the DHCR24 LXRE can mediate transcriptional activation by ligand-bound LXR.
We next examined the ability of the DHCR24 LXRE to mediate LXR induced transcription in another cell line. HEK293 cells were transfected with the DHCR24 or NR1H3 LXRE luciferase reporters along with expression vectors for LXRα or LXRβ.
Cell transfected with a control reporter lacking an LXRE and an expression vector for
LXRα displayed no responsiveness to LXR ligands (Fig. 4a ). Cells transfected with the DHCR24 LXRE reporter and no LXR expression vector showed some responsiveness to LXR ligands consistent with previous reports that HEK293 cells express some LXR (Yoshikawa et al., 2003) (Fig. 4b) . Overexpression of either LXRα (Fig. 4c) 
Discussion
The Seladin-1 gene was originally identified based on its reduced expression in the brains of individuals affected by AD (Iivonen et al., 2002) . This gene was later shown to encode 3β-hydroxysterol-∆24 reductase (DHCR24), an enzyme critical for the final step in cholesterol biosynthesis (Waterham et al., 2001 ). Seladin-1/Dhcr24 has been shown to modulate membrane cholesterol levels and lipid raft formation (Crameri et al., 2006) . Lipid rafts, cholesterol rich microenvironments on the cells surface, are important in localization of many membrane associated proteins and are responsible for creating areas of enriched components of signaling or enzymatic pathways (Simons and Toomre, 2000) . In a whole genome screen for LXR binding sites, we discovered that this gene contained a functional LXRE. We also found that Seladin-1/Dhcr24 gene expression is potentially due to low plasma cholesterol content (Ledesma et al., 2003) , it has been suggested that this leads to aberrant APP processing and Aβ peptide accumulation and thus, AD (Abad-Rodriguez et al., 2004) . These data are consistent with the proposed role of Seladin-1/DHCR24 in AD, where expression levels of this gene are low in AD brains (presumably leading to low plasma cholesterol levels and aberrant APP processing) (Greeve et al., 2000) . Increasing Seladin-1/DHCR24 expression appears to confer resistance to neurodegeneration in several models (Cecchi et al., 2008; Crameri et al., 2006; Greeve et al., 2000; Kuehnle et al., 2008) . It has been proposed that pharmacological enhancement of Seladin-1 activity may be an effective Aβ-lowering approach to the treatment of AD (Crameri et al., 2006) . Thus, the results we show here are intriguing because previous studies have indicated that LXR agonists are effective in reducing Aβ peptide accumulation and AD pathology in rodent models (Brown et al., 2004; Koldamova et al., 2003; Koldamova et al., 2005; Riddell et al., 2007; Sun et al., 2003; Zelcer et al., 2007) . Previous studies have attributed the protective effects of LXR agonists to increased ABCA1 expression (Koldamova et al., 2003; Koldamova et al., 2005 ) (Sun et al., 2003) . However, no abnormal Aβ accumulation has been noted in Abca1 null mice (Burns et al., 2006) and no premature AD has been noted in Tangier disease patients (mutated ABCA1 gene) suggesting that other mechanisms may also be mediating the protective effects of LXR agonists.
We were intrigued by the observation that expression of Seladin-1/Dhcr24 was not altered in the brains from LXRβ null mice. It is unlikely that LXRα would be playing a compensatory role since LXRβ is the predominant form of LXR in the brain (Whitney et al., 2002) . This is, in fact, consistent with the lack of AD-like pathology in This article has not been copyedited and formatted. The final version may differ from this version. 
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